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Individual PCR amplification tests have been developed for three UK CF epidemic strains, the Liverpool epidemic strain (LES), Midlands 1
and the Manchester epidemic strain (MES). We report a simple diagnostic multiplex PCR test that can be used to screen for all three of these
strains. To evaluate the test, we screened collections of LES, MES and Midlands 1 isolates, along with various CF and non-CF non-epidemic
Pseudomonas aeruginosa strains. The test was 100% sensitive and 100% specific in the identification of these UK CF epidemic strains.
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Once established as chronic, infection of CF patients with
Pseudomonas aeruginosa is impossible to eradicate. The
original view was that CF patients acquired their own unique
strains of P. aeruginosa from the environment. However,
transmission of P. aeruginosa between CF has been reported in
Europe [1–4] and Australia [5,6]. In the UK, the three most
widely studied epidemic strains are the Liverpool epidemic
strain (LES) [1,7], the Midlands 1 strain [8,9], and the
Manchester epidemic strain (MES) [10]. A survey of CF
centres in England and Wales [3] showed that the LES was the
most common clone amongst CF isolates, followed by the
Midlands 1 strain. Specifically, 11% of CF patients were☆ This paper is dedicated to the memory of Professor Tony Hart, an
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doi:10.1016/j.jcf.2007.09.002infected with the LES, which was found in 48% of the CF
centres in the UK. The same survey identified the Midlands 1
strain in 10% of isolates and in 29% of centres and the MES in
1% of isolates and in 10% of centres [3]. The LES has also been
reported in Scotland [11] and is associated with increased
patient morbidity [12].
Individual PCR amplification tests have been described
previously for the LES [13,14], Midlands 1 [9] and the MES
[10]. In each case subtractive hybridisation was used to identify
genes or genomic islands specific to the individual strains. In
this study we report a combined multiplex PCR (M-PCR) assay
to monitor for the presence of all three of these UK CF epidemic
strains.
2. Materials and methods
The panel of P. aeruginosa strains and isolates used in this
study have been described previously [9,14] and consisted of 30
LES isolates, 12 Midlands 1 isolates, 12 MES isolates, and 13
genetically-distinct non-epidemic CF isolates and the control
strains clone C [15], PA01 [16] and PA14 [17]. All isolates hadd by Elsevier B.V. All rights reserved.
Table 1
Oligonucleotide primers used in this study
Name Oligonucleotide (5′ to 3′) Target Amplicon size (bp) Reference
PS21F AAGCAGGCCAGCGTGTCTA LES-PS21 364 [13]
PS21R AAAACGTAGCAAGCAGTG (LES)
LESF9F AACACTTGCTCCATCTGC LESF9 431 [14]
LESF9R CACGATATCCAGCAAGAC (LES)
MID1F TTGCGCTCCATCGTTTGA MID1 649 [9]
MID1R CTCCAGATGCCTACGAAA (Midlands 1)
MA15F GTCGGCAGATAGCCTTTGTC MA15 308 [10]
MA15R CGACTAATACCCGTCGCTTC (MES)
341f CCTACGGGAGGCAGCAG 16S rRNA 560 [18]
518r CCGTCAATTCMTTTGAGTTT (Bacteria)
pA AGAGTTTGATCCTGGCTCAG 16S rRNA 1500 [21]
pH AAGGAGGTGATCCAGCCGCA (Bacteria) Approximately
UNI2 GACTCCTACGGGAGGCAGCAG 16S rRNA 1020 [22]
UNI5 CTGATCCGCGATTACTAGCGATTC (Bacteria) Approximately
PAL1 ATGGAAATGCTGAAATTCGGC oprL 504 [23]
PAL2 CTTCTTCAGCTCGACGCGACG (P. aeruginosa)
PA-GS-F GACGGGTGAGTAATGCCTA 16S rRNA 618 [24]
PA-GS-R CACTGGTGTTCCTTCCTATA (Pseudomonas)
PA-SS-F GGGGGATCTTCGGACCTCA 16S rRNA 956 [24]
PA-SS-R TCCTTAGAGTGCCCACCCG (P. aeruginosa)
616 V AGAGTTTGATYMTGGCTC 16S rRNA 1500 [25]
630R CAKAAAGGAGGTGATCC (Bacteria) Approximately
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electrophoresis (PFGE).
Oligonucleotide primers (Sigma-Genosys) used for PCR
amplification are listed in Table 1 along with the annealing
temperatures used. DNA for PCR amplification was prepared by
making a suspension of a few colonies in water and boiling for 5–
10min. Following centrifugation 1 µl of this crudeDNAwas used
directly in 25 µl volumes containing 1.25 U of GoTaq DNA
polymerase (Promega), 1×TaqMaster (Helena Biosciences),
300 nM each primer, 1×Taq buffer, 2.5 mM MgCl2 and
100 mM nucleotides (dATP, dCTP, dGTP, dTTP). As an
alternative polymerase system Fermentas Taq polymerase
(Helena Biosciences) was also used with the relevant buffer
supplied by the manufacturer. Amplifications were carried out for
30 cycles consisting of 95 °C (1 min), annealing temperature
(1 min) and 72 °C (2 min) with an additional extension time at
72 °C (10 min) following completion of the 30 cycles, either in an
Eppendorf MasterCycler or a multigene II (Labnet) thermal
cycler. For assay development and positive controls a mixture of
representative isolates of the LES, MES and Midlands 1 strains
was used.
3. Results
We sought to include primer sets for the amplification of
several target amplicons within the same assay. In particular, the
assay was designed to target two LES markers, PS21 [13] and
LESF9 [14], a Midlands 1 marker, MID1 [9], a marker for the
MES, MA15 [10], and a sample control. Combinations of
primers were tested using temperature gradient PCR amplifi-
cation in order to vary the annealing temperature. For the
control we tested seven primer sets for amplification of bacterial
16S rRNA genes or the oprL gene (Table 1). Although the fourepidemic strain marker primer sets were readily compatible over
a range of annealing temperatures (data not shown), we were
only able to obtain all of the relevant amplicons from a mixture
of the three epidemic strains when combining these primer sets
with the 341f/518r primer set [18] for the amplification of
bacterial 16S rRNA genes (Fig. 1A). An annealing temperature
of 53 °C was chosen for the M-PCR assay on the basis of the
temperature gradient profile (Fig. 1A).
We carried out a blind test of the M-PCR assay on a panel of
LES, MES, Midlands 1 and non-epidemic strain P. aeruginosa
isolates whereby the test was carried out without prior
knowledge of the true identity of any isolates. These isolates
had previously been identified using PFGE. Example assays are
shown in Fig. 1B One MES isolate yielded an additional non-
specific band that made interpretation more difficult but, other
than that, the test was 100% sensitive and specific when applied
to our panel. We selected a sub-panel of nine isolates
representing two isolates of each of the epidemic strains and
three non-epidemic strains. These were used to carry out M-
PCR assays using Fermentas Taq polymerase (Helena Bios-
ciences) instead of GoTaq (Promega), and using a Labnet
Multigene thermal cycler instead of the Eppendorf MasterCy-
cler. In each case the M-PCR assay results were clear, although
with GoTaq polymerase a faint additional band of b300 bp
could be seen with some isolates (Fig. 1C).
4. Discussion
Since chronic infection with P. aeruginosa is associated with
greater morbidity and mortality in CF patients [19,20] it is
important to keep CF patients free from P. aeruginosa infection
for as long as possible. With increasing evidence for the
existence of transmissible strains the onus is on CF clinics to
Fig. 1. Agarose gel (2%) electrophoresis of M-PCR assay products.
(A) Temperature gradient PCR amplification using a control template of all
three epidemic strains with varying annealing temperatures of, for lanes 1–10
respectively, 45.3, 46.4, 48.2, 50.4, 53.0, 55.8, 58.5, 61.0, 63.1 and 64.7 °C.
(B) Example PCR amplicons from a blind test of isolates. Isolates were
identified as LES (lanes 4 and 6), MES (lanes 1 and 3), Midlands 1 (lane 7) or
non-epidemic (unique) P. aeruginosa (lanes 2 and 5). (C) M-PCR assay using
GoTaq polymerase (Promega). MID; Midlands 1. M; 1 kb-plus size marker
(Invitrogen). C; Control mixture of LES, MES and Midlands 1.
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policies. A simple PCR test should prove to be a useful tool for
better informing clinicians charged with the responsibility for
making decisions about segregation in order to prevent
epidemic spread of P. aeruginosa strains amongst patients. In
addition, widespread use of simple PCR assays such as this
should enable the community to better monitor the spread of
epidemic strains.
The M-PCR assay reported in this study identifies three of
the main UK epidemic strains in a single test. Since reporting
the PS21 test for the LES [13] we [14] and others [10] have
noted the occurrence of occasional false positives. In order to try
and address this issue we now use two PCR markers for the LES
[14]. Thus far we have not identified any non-LES
P. aeruginosa isolates testing positive for both markers, nor
have false PCR-positives for either the Midlands 1 or the MES
markers been reported. However, it is possible that such strains
exist. Thus, we would suggest that the M-PCR test is used for
initial screening purposes, but that any suspected positives
should be followed up using additional molecular tests such as
PFGE or random amplified polymorphic DNA analysis.
Control strains for each of the epidemic strains will be made
available on request by Tyrone Pitt (Tyrone.Pitt@hpa.org.uk) or
Craig Winstanley (C.Winstanley@liv.ac.uk). In addition, it isimportant that regular molecular typing is carried out to identify
any emerging epidemic strains not covered by this test. It is
widely recognised that PCR diagnostic tests are quicker and
cheaper than typing using PFGE and others have sought to
quantify these benefits [26]. Although the savings, both
financial and temporal, may vary depending on the expertise
and equipment available within individual laboratories, we
believe that the M-PCR assay represents a considerable
improvement on the necessity for PFGE analysis of all CF
isolates.
Acknowledgement
This work was undertaken under the framework of the UK
CF Microbiology Consortium, an initiative funded by the Big
Lottery Fund in association with the Cystic Fibrosis Trust.
References
[1] Cheng K, Smyth RL, Govan JR, et al. Spread of beta-lactam-resistant Pseu-
domonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639–42.
[2] FlugeG,Ojeniyi B,HoibyN, et al. Typing ofPseudomonas aeruginosa strains
in Norwegian cystic fibrosis patients. Clin Microbiol Infect 2001;7:238–43.
[3] Scott FW, Pitt TL. Identification and characterization of transmissible
Pseudomonas aeruginosa strains in cystic fibrosis patients in England and
Wales. J Med Microbiol 2004;53:609–15.
[4] Jelsbak L, Johansen HK, Frost AL, et al. Molecular epidemiology and
dynamics of Pseudomonas aeruginosa populations in lungs of cystic
fibrosis patients. Infect Immun 2007;75:2214–24.
[5] Armstrong D, Bell S, Robinson M, et al. Evidence for spread of a clonal
strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J Clin
Microbiol 2003;41:2266–7.
[6] O'Carroll MR, Syrmis MW, Wainwright CE, et al. Clonal strains of
Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur
Respir J 2004;24:101–6.
[7] Fothergill JL, Panagea S, Hart CA, Walshaw MJ, Pitt TL, Winstanley C.
Widespread pyocyanin over-production among isolates of a cystic fibrosis
epidemic strain. BMC Microbiol 2007;7:45.
[8] Chambers D, Scott F, Bangur R, et al. Factors associated with infection by
Pseudomonas aeruginosa in adult cystic fibrosis. Eur Respir J 2005;26:651–6.
[9] Smart CH, Scott FW,Wright EA, et al. Development of a diagnostic test for the
Midlands 1 cystic fibrosis epidemic strain ofPseudomonas aeruginosa. J Med
Microbiol 2006;55:1085–91.
[10] Lewis DA, Jones A, Parkhill J, et al. Identification of DNA markers for a
transmissible Pseudomonas aeruginosa cystic fibrosis strain. Am J Respir
Cell Mol Biol 2005;33:56–64.
[11] Edenborough FP, Stone HR, Kelly SJ, Zadik P, Doherty CJ, Govan JR.
Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need
for segregation. J Cyst Fibros 2004;3:37–44.
[12] Al Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw
MJ. Increased morbidity associated with chronic infection by an
epidemic Pseudomonas aeruginosa strain in CF patients. Thorax
2004;59:334–6.
[13] Parsons YN, Panagea S, Smart CH, Walshaw MJ, Hart CA, Winstanley C.
Use of subtractive hybridization to identify a diagnostic probe for a cystic
fibrosis epidemic strain of Pseudomonas aeruginosa. J Clin Microbiol
2002;40:4607–11.
[14] Smart CH, Walshaw MJ, Hart CA, Winstanley C. Use of suppression
subtractive hybridization to examine the accessory genome of the Liver-
pool cystic fibrosis epidemic strain of Pseudomonas aeruginosa. J Med
Microbiol 2006;55:677–88.
[15] Romling U, Wingender J, Muller H, Tummler B. A major Pseudomonas
aeruginosa clone common to patients and aquatic habitats. Appl Environ
Microbiol 1994;60:1734–8.
261J.L. Fothergill et al. / Journal of Cystic Fibrosis 7 (2008) 258–261[16] Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of
Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature
2000;406:959–64.
[17] Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM.
Common virulence factors for bacterial pathogenicity in plants and
animals. Science 1995;268:1899–902.
[18] Muyzer G, de Waal EC, Uitterlinden AG. Profiling of complex microbial
populations by denaturing gradient gel electrophoresis analysis of
polymerase chain reaction-amplified genes coding for 16S rRNA. Appl
Environ Microbiol 1993;59:695–700.
[19] Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudo-
monas aeruginosa and other predictors of mortality and morbidity in
young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91–100.
[20] Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in
children with cystic fibrosis after Pseudomonas aeruginosa acquisition.
Pediatr Pulmonol 2001;32:277–87.
[21] Edwards U, Rogall T, Blocker H, EmdeM, Bottger EC. Isolation and direct
complete nucleotide determination of entire genes. Characterization of a
gene coding for 16S ribosomal RNA.Nucleic Acids Res 1989;17:7843–53.
[22] Mahenthiralingam E, Bischof J, Byrne SK, et al. DNA-Based diagnostic
approaches for identification ofBurkholderia cepacia complex,Burkholderiavietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Bur-
kholderia cepacia genomovars I and III. J Clin Microbiol 2000;38:3165–73.
[23] De Vos D, Lim Jr A, Pirnay JP, et al. Direct detection and identification of
Pseudomonas aeruginosa in clinical samples such as skin biopsy
specimens and expectorations by multiplex PCR based on two outer
membrane lipoprotein genes, oprI and oprL. J Clin Microbiol 1997;35:
1295–9.
[24] Spilker T, Coenye T, Vandamme P, Lipuma JJ. PCR-based assay for
differentiation of Pseudomonas aeruginosa from other Pseudomonas
species recovered from cystic fibrosis patients. J Clin Microbiol 2004;42:
2074–9.
[25] Juretschko S, Timmermann G, Schmid M, et al. Combined molecular and
conventional analyses of nitrifying bacterium diversity in activated sludge:
Nitrosococcus mobilis and Nitrospira-like bacteria as dominant popula-
tions. Appl Environ Microbiol 1998;64:3042–51.
[26] Syrmis MW, O'Carroll MR, Sloots TP, et al. Rapid genotyping of Pseu-
domonas aeruginosa isolates harboured by adult and paediatric patients
with cystic fibrosis using repetitive-element-based PCR assays. J Med
Microbiol 2004;53:1089–96.
